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Abstract: Liver surgery is one of the most complex surgical interventions with high risk and potential for complications. Posthepatectomy
liver failure (PHLF) is a serious complication of liver surgery that occurs in about 10% of patients undergoing major liver surgery. It is the
main source of morbidity and mortality. Appropriate surgical techniques and intensive care management are important in preventing
PHLF. Early start of the liver support systems is very important for the PHLF patient to recover, survive, or be ready for a liver transplant.
Nonbiological and biological liver support systems should be used in PHLF to prepare for treatment or organ transplantation. The
definition of the state, underlying pathophysiology and treatment strategies will be reviewed here.
Key words: Posthepatectomy liver failure, liver surgery, prevention, treatment

1. Introduction
Liver surgery is one of the most complex surgical
interventions with high risk and potential for complications.
Postohepatectomy liver failure (PHLF) is the main source
of morbidity and mortality after major liver surgery.
Despite major improvements in results after major liver
surgery due to improvements in the maintenance and
operation technique in the intensive care units, PHLF
remains one of the most serious complications of major
liver surgery [1,2]. Although a lower rate of PHLF has
been reported in many studies in East Asian countries
(1–2%); PHLF remains an important source of morbidity
and mortality.
2. Definition
Although the definition of PHLF varies greatly between
countries and groups, in 2011, the International Study
Group of Liver Surgery (ISGLS) proposed a standardized
definition and rating of PHLF after evaluating more than
50 studies. According to ISGLS; the deterioration (increase
in INR and bilirubin levels) in the synthesis, excretion,
and detoxification functions of the liver after liver surgery
(day 5 or later) was defined as PHLF [1]. The incidence
is reported at around 10% [1,2]. The highest acceptable
mortality rate for major liver resection (LR) is considered
as <10% and PHLF is shown as the most important
(between 60% and 100%) cause of mortality [3]. Twenty-

five percent of patients who die due to PHLF are lost after
the first month postoperatively [4].
3. Pathophysiology
Hepatocytes and nonparenchymal cells must be present
in adequate numbers for healthy regeneration of the liver
remnant. The patency of inflow and outflow of remnant
liver is another important factor for regeneration. In
addition, factors that promote ongoing parenchymal
damage after LR, notably small for size syndrome (SFSS),
sepsis, and ischemia-reperfusion (IR) injury must be
absent [5,6]. Hyperperfusion theory is the most widely
accepted explanation of SFSS. Reduction in parenchymal
volume and constant blood flow lead to a cycle of
sinusoidal dilatation, shear stress, hemorrhagic infiltration,
centrilobular necrosis, prolonged cholestasis, impaired
synthetic function, and inhibition of cell proliferation [7,8].
The population of Kupffer cells is reduced after LR.
Therefore, immune response is impaired and susceptibility
to infection is increased. A relative increase in endotoxin
delivery to the liver remnant is beneficial as it leads to
activation of Kupffer cells and initiation of regeneration
[9]. However, prolonged endotoxemia in sepsis leads to
Kupffer cell dysfunction, impaired liver regeneration, and
hepatic necrosis [10,11].
After the induction of ischemia, the complement
cascade is activated, leading to Kupffer cell activation,
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generation of reactive oxygen species, and endothelial
cell damage. In the reperfusion period, a cycle of cell
adhesion molecule upregulation, cytokine release, T cell
and polymorphonuclear cell recruitment and activation
are initiated. Finally, microvascular injury, Kupffer cellmediated inflammation, and hepatocyte death occur
[12,13].

4. Risk and prevention
Risk factors for PHLF are summarized in Table 1.
PHLF is divided into three subgroups according to the
classification made by ISGLS (Table 2) [1]. Patients in
group A with temporary liver dysfunction that do not
require invasive treatment should be monitored. Group
B and C patients with multiple organ failure or severe

Table 1. Risk factors for PHLF.

Patient-dependent factors

- Diabetes mellitus
- Obesity
- Liver damage due to chemotherapy
- Malnutrition
- Kidney failure
- Hiperbilirubinemia
- Thrombocytopenia
- Lung disease
- Cirrhosis/chronic liver disease
- Age > 65

Surgery-dependent factors

- Bleeding during surgery > 1200 mL
- Massive transfusion in surgery
- Vascular resection requirement
->50% resection of liver volume
- Major hepatectomy including right lobe
- Excessive dissection of the hepatoduodenal ligament
- Remnant liver volume <25%
- Operating time > 240 min.
- Prolonged application of Pringle or TVE maneuver

Postoperative factors

-Postoperative bleeding
-İntraabdominal infection

Table 2. PHLF classification by ISGLS (International Study Group of Liver Surgery).
Group

Clinical description

Diagnosis

Symptoms

Mortality

A

-Urine Output >0.5 mL/kg/h
-BUN <150 mg/dL
Impaired liver function
-Oxygen saturation >90%
-INR <1.5

None

%0

B

Deviation from the
expected postoperative
course, no need for
invasive support

-Urine Output ≤0.5 mL/kg/h
-BUN <150 mg/dL
- Despite the oxygen supply oxygen saturation <90%
-INR ≥1.5, <2.0

-Acid
-Weight gain
-Mild respiratory failure
-Confusion
-Encephalopathy

%12

C

Multiple organ failure
requiring invasive
support

-Urine output ≤0.5 mL/kg/h
-BUN ≥150 mg/dL
- Despite high fractionated oxygen support oxygen
saturation ≤85%
-INR ≥2.0

- Kidney failure
- Hemodynamic instability
- Respiratory failure
%54
- Massive ascites
-Encephalopathy

PHLF: posthepatectomy liver failure; BUN: blood urea nitrogen; INR: international normalized ratio.
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liver failure should be monitored under intensive care
conditions. Patients should be closely monitored for signs
of systemic inflammatory response syndrome (SIRS).
Serum bilirubin, aminotransferase, albumin, international
normalized ratio (INR), ammonia, lactate, and, C-reactive
protein (CRP) levels should be closely monitored with
serial measurements. Also, it is recommended that the
patient group, whose antithrombin-3 activity measures
below 61.5% on the first postoperative day, should be
carefully monitored for failure [14]. Whether there is
a problem with arterial, portal venous blood supply or
venous outflow (hepatic veins) of the liver in patients
who develop PHLF should be evaluated by Doppler
ultrasonography, computerized tomography (CT),
or angiography. In the presence of arterial stenosiscongestion, tissue plasminogen activator (t-PA) infusion
or balloon angioplasty can be applied to the relevant area;
the factors that reduce or stop the flow of the artery of
interest should be eliminated with relaparotomy, and if
necessary, reanastomosis should be performed [15]. In the
presence of portal vein stenosis or thrombosis, systemic
heparinization should be initiated with caution. In case of
stenosis or bending, additionally, t-PA infusion can be tried
by percutaneous entry into the portal vein and this stenosis

or bending can be corrected by the endovascular stent in
the early period. The obstructive jaundice condition in the
postoperative period that may occur after surgery should
also be examined, and the treatment process should be
carefully managed in case of its presence (percutaneous
drainage or relaparotomy is planned according to the
patient’s condition) [16]. Strategies for prevention of PHLF
are summarized in Table 3 [17–19].
5. Management and treatment
5.1. Medical support therapy
The approach to patients with PHLF starts with medical
support therapy. When SIRS is observed in patients,
hypotension and relative hypovolemia, observed due to
decreased systemic vascular resistance should be monitored
by invasive monitoring. Colloid-weighted fluids should be
used in fluid replacement, and albumin support should
be provided. Vasoactive agents may be required in cases
that do not respond despite adequate volume support.
Extracellular fluid accumulation should be avoided [20].
Hydrocortisone support is recommended for the control
of persistent lactic acidosis caused by hypoperfusion
and vasopressor agent use. N-acetyl cysteine should also
be administered in the treatment of liver failure [21,22].

Table 3. Strategies for prevention from PHLF.

Safe surgery group in
cirrhotic patients

-Child-Pugh Group A patients
- Platelets >100,000/mL
- No clinically apparent portal hypertension
- Liver volume remaining between > 40% and 50%
- Indocyanine green retention <15%

Preoperative strategies

- Increasing the liver volume left behind by portal vein embolization
- Ensuring overweight patients to lose weight before surgery
- Nutritional support
- Control of diseases that will cause additional morbidity
- Preoperative measurement of liver stiffness by transient elastography
- Preoperative measurement of spleen thickness

Intraoperative
strategies

- Avoiding unnecessary dissection of the hepatoduodenal ligament, and if necessary, carefully dissecting
- Minimizing blood loss by performing parenchymal resection under low central venous pressure
- Ischemic preparation
- Application of intermittent Pringle maneuver
- Hypothermic liver protection
- Surgery combined with ablation treatments
- Two-stage resection
- Avoiding blood transfusion as much as possible
- Compliance with the principles of hemostasis

Postoperative strategies

- Early detection and treatment of postoperative bleeding
- Early detection and treatment of postoperative bile duct obstruction or bile leak
- Early detection and treatment of postoperative intra-abdominal infection

PHLF: posthepatectomy liver failure.
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Proton pump inhibitor therapy should be applied to
prevent the development of stress ulcers. Early intubation
and mechanical ventilator therapy may be needed since
patients with liver failure may develop acute lung injury
(PaO2 / FiO2 ratio < 300 mmHg) or acute respiratory
distress syndrome (PaO2 / FiO2 ratio < 200 mmHg). Tidal
volume should be 6 mL/kg in adult ventilator therapy
and PaO2 should be kept above 80 mmHg. Also, high
positive end-expiratory pressure (PEEP) administration
should not be applied at high levels as it will cause hepatic
congestion, portal hypertension, acid development, and
decreased liver regeneration. Hyperventilation (PCO2;
25–30 mmHg) protocol should be applied to decrease the
intracranial pressure in patients who need mechanical
ventilator treatment. The most important underlying
cause of the encephalopathy in the liver failure is ammonia
accumulation and cerebral edema due to hyponatremia.
Since brainstem herniation or hypoxic brain injury are
complications that may develop due to brain edema
and cause a rapid deterioration of the patient, treatment
preventing the formation of brain edema should be started
(mannitol therapy, hyperventilation, sodium thiopentone,
hypertonic fluid therapy, etc.). [20,23]. Treatment using
oral rifaximin, laxative (lactulose), and enema limits
the formation of ammonia. In patients with grade 3–4
encephalopathy, monitoring intracranial pressure, close
blood sugar monitoring, and controlled hypothermia
are recommended [3]. The development of resistant
hypoglycemia (disruption of hepatic gluconeogenesis
and hyperinsulinemia) is a poor prognostic marker. First,
enteral nutrition should be applied and parenteral nutrition
should be given to patients with limited oral intake. The
daily calorie need of patients should be calculated between
25 and 35 kcal/kg and daily protein support between 1 and
1.2 g/kg. Branched-chain amino acid solutions (leucine,
isoleucine, or valine) should be preferred to meet protein
needs. Most of the calorie needs should be met with
carbohydrate and fat solutions. Acute tubular necrosis due
to SIRS or development of hepato-renal syndrome (HRS)
due to underlying liver disease should be monitored
and treatment of complications such as hypokalemia
(resistant to diuretic therapy), hypophosphatemia oliguria,
hyponatremia, and water retention should be carried
out immediately [20,21]. Massive ascites is particularly
observed in patients with preoperative portal hypertension.
Furosemide/spironolactone should be administered at
a rate of 2/5 (20 mg / 50 mg) in diuretic treatment. The
diuretic response may be limited due to acute renal injury
due to surgery, SIRS, or HRS. Also, diuretic use deepens
the existing hyponatremia. When sodium levels fall below
120 mEq/L, diuretic therapy should be discontinued and
patients with intravascular volume deficits should be given
albumin support. Intermittent paracentesis should be
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performed in case of impaired patient comfort, restricted
breathing, impaired oral intake, or leakage of ascites from
the surgical area (in patients with liver failure). In the case
of paracentesis more than 5 L, 8 g of albumin replacement
should be performed for each liter taken to prevent
renal failure, hyponatremia, and hypotension. TIPS or
peritoneovenous shunt may be required in the presence of
prolonged acid (4–6 weeks and above postoperatively in
liver failure patients). Bacterial infections (80%) are found
in the majority of patients with liver failure. Although
prophylactic antibiotic therapy is not recommended, it is
recommended to start broad-spectrum antibiotic therapy
without waiting for culture results in the presence of the
smallest suspicion [20,21]. It is also recommended to add
antifungal drugs to treatment.
Factor II, VII, IX, and X dysfunction occurs depending
on the decarboxylation of the degraded vitamin K in
the liver failure. Also, disorders of thrombocytopenia
and thrombocyte function are observed due to renal
dysfunction and uremia. Fresh frozen plasma (FFP) is
used to control oncotic pressure and prevent INR rise.
However, large amounts of FFP transfusions should be
used with caution as they can lead to the development of
brain edema and acute lung injury. The risk of bleeding
should be taken into account during deep vein thrombosis
prophylaxis application to patients.
5.2. Liver support systems in treatment
These systems are developed to support patients with liver
failure until the patients’ condition improves or a transplant
is made. The complex physiological, biochemical, and
metabolic functions of the liver do not make it possible to
perform a truly complete replacement therapy. Also, the
complexity of the pathophysiology of liver failure, especially
the inability to reveal the underlying mechanisms affecting
prognosis, such as cerebral edema and encephalopathy,
is an important barrier to supportive therapies.
Approaches to liver support are divided into two groups
as nonbiological and biological systems. Nonbiological
systems are based on nonspecific detoxification using a
limited permeable membrane. Biological support systems
try to create a detoxification environment close to natural
liver tissue by utilizing various cell (hepatocyte) cultures
[20,21,24]. Nonbiological support units are used in most of
the European countries and our center due to the high cost
of biological systems, technical difficulties in supplying
hepatocytes and maintaining their viability for a long time.
5.2.1. Nonbiological liver support
Nonbiological support units are applied with extracorporeal
pump machines with different features. Generally, there are
options on the used pump machines that allow different
support units to be applied. Applications are made through
2-way wide lumen catheters placed in the subclavian,
internal jugular, or femoral vein. The main purpose in
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these applications is to remove the molecules other than
essential hormones, growth factors, immunoglobulins,
coagulation factors, and complement system proteins
(molecular weight > 50–60 kDa), which are bound to
carrier proteins, from circulation. In this way, water-soluble
toxins (ammonia, urea, lactate, creatinine, etc.) and oilsoluble toxins (bile acids, bilirubin, aromatic amino acids,
short and medium-chain fatty acids, etc.) can be effectively
removed. Also, tumor necrosis factor (TNF)-α (17.5 kDa),
Interleukin (IL)-1β (17 kDa), IL-6 (21 kDa), IL-8 (8 kDa)
and IL-10 (18.7 kDa) are among the main cytokines that
play an active role in the etiopathogenesis of liver failure
and removing them from circulation also aims to correct
the clinical picture of the patients. [25,26].
Nonbiological liver support systems are divided into 4
main groups [27];
I. Continuous renal replacement therapies (CRRT);
continuous venovenous hemodialysis, continuous
venovenous
hemofiltration
(CVVF),
continuous
venovenous hemodiafiltration (CVVHDF), continuous
slow ultrafiltration, and continuous high-flux dialysis
(Figure 1)
II. Plasmapheresis, plasma exchange, and continuous
plasma filtration adsorption
III. Hemoperfusion
IV. Albumin dialysis
5.2.1.1. Continuous renal replacement therapies (CRRT)
Although it is usually done by a large lumen central
catheter, it can also be done using arteriovenous (AV)
fistula. Venous blood from the patient enters the peristaltic
pump with a venovenous circuit. According to the
intermittent hemodialysis application, it is aimed to lessen
the patient’s hemodynamics by drawing fluid continuously
in a limited volume [26]. During the cycle, coagulation is
prevented using citrate or heparin. CRRT is mainly used
to extract excess fluid in the extracellular space. They are
used effectively in removing toxins that are not bound
to albumin [27,28]. The membranes used in the units
are made of biocompatible material (polyacrylonitrile,
polymethylmethacrylate, etc.) to limit the activation of
complement and other humoral systems. The tendency
towards coagulation is minimal due to the high
ultrafiltration constant. Dialysate and replacement fluid
are used during the procedure with the selected CRRT
technique. Dialysate is the liquid in which toxins and waste
materials collected from the blood exist. The replacement
fluid is a balanced electrolyte solution added to the venous
blood which returns to the patient to maintain body
homeostasis before or after the filter through which the
blood passes. It is aimed to maintain the normal electrolyte
and acid-base state while forming the composition. The
sodium concentration in the liquids used is 150 mmol/L.
If necessary, KCl, calcium, and magnesium can be added.

The pH can be buffered using bicarbonate or lactate.
Although heparin (nonfractionated) is often preferred
for anticoagulation of the system, low molecular weight
heparin, citrate, prostacyclin, or nafamostatmesylate can
also be used [26,29]. After the procedure, the blood is given
to the patient again with the replacement fluid or without
replacement. Five different CRRTs can be made. Diffusion,
convection, or a combination of both methods used in
CRRT. The diffusion method is based on the exclusion of
toxins dissolved in the blood. Toxins pass from one side
of the semipermeable membrane (low permeability) to the
other, depending on the electrochemical (concentration)
gradient. The molecules move from the high concentration
section to the low concentration section. Low molecular
weight (5–15 kDa) toxins such as acid, potassium,
and uremic toxins are discarded with this method but
molecules reaching up to 30 kDa can be removed from the
circulation with the use of synthetic polymeric membranes
(polyacrylonitrile, polymethylmethacrylate, etc.). The
convection method is based on ensuring the excretion of
toxins dissolved in the blood. It works with a mechanism
like the normal function of the human kidney. Solubles
dissolve in the high-pressure zone with solvent and
move from the high-pressure section to the low-pressure
section through the high permeability membrane. In
this mechanism, the transmembrane pressure gradient
is important. Convection depends on filtration rate,
membrane permeability, and soluble concentration.
Medium-sized molecules (<60 kDa) are removed more
effectively than in the diffusion method [23,24,26].
5.2.1.2. Plasmapheresis, plasma exchange, and
continuous plasma filtration adsorption
In plasma exchange application, while plasma which is
separated from the blood of the patient with the help of
high permeability membrane is taken out, the patient is
given fresh frozen plasma and so the change is made. In
the plasmapheresis method, plasma separated from the
patient’s blood by centrifugation method is not replaced
[27]. In continuous plasma filtration adsorption (CPFA)
method, patient’s plasma is filtered with a high permeability
plasma filter that allows it to pass through a bed of
adsorbent material (carbon or resins) (Figure 2). Each
treatment method, like the nonbiological liver support
treatments mentioned earlier, is applied by central venous
catheter and with module alteration of the same machines.
The aim is to remove circulating antibodies and reduce
cytokine load [29–31]. Large molecules ( >60 kDa) are
removed using this method. Since these molecules include
molecules such as growth hormones, immunoglobulins
(150–900 kDa), albumin (66.3 kDa), transferrin (76
kDa), fibrinogen (341 kDa), the plasmapheresis method
is especially used in many autoimmune diseases and
ABO-incompatible or cross-match positive kidney
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Figure 1. Continuous types of renal replacement therapy and basic working mechanisms. V: vein; D: dialysate; R: replacement
solution; UF: ultrafiltrate; UFc: ultrafiltrate control pump.

transplantation. The plasma exchange method is used to
remove bilirubin effectively from circulation, especially
in cases of hyperbilirubinemia [32,33]. In the treatment
of liver failure, plasma exchange, or plasmapheresis
treatment together with CRRT is recommended [34–36].
In this way, it is aimed to ensure that the growth factors
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and hormones that remain useful for the patient remain
in circulation. In a study published in Japan, CVVHDF
and plasma exchange methods were used together in the
treatment of acute liver failure. Patients’ consciousness
improved with this treatment and brain edema and HRS
did not develop during treatment [37]. In this study, the
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Figure 2. Working mechanisms of plasmapheresis and plasma
exchange treatments. V: vein; PR: plasma replacement; C:
centrifuge.

average number of sessions is 21 (4–30), 20% of patients
with liver failure due to acute hepatitis B infection, and
57% of patients with liver failure due to an unknown cause.
In the plasma exchange application, the sessions take 4 h
and the plasma removed from the patient (40–50 mL/kg/
session) is replaced with fresh frozen plasma (8–10 units/
session) or Human albumin (5% H. Albumin, 2500 mL/
session) or saline (3000 mL/session) [29,30].
5.2.1.3. Hemoperfusion
Hemoperfusion is the process of passing high blood
volume (300 mL/min) of patient blood through an
adsorbent surface especially to remove water-soluble
toxins (ammonia, urea, lactate, creatinine, etc.) from
the blood and give it back to the patient. The adsorbable

chemical sorbents used in hemoperfusion are resin,
activated carbon, or coal. Coal hemoperfusion is the
most studied nonbiological liver supplement treatment.
Initially, although it was observed that it was more
effective than hemodialysis treatment in survival and
improvement of the neurological picture in patients with
liver failure; this difference could not be demonstrated in
controlled studies. However, activated charcoal is still used
in the most effective nonbiological liver support systems
(MARS, PROMETHEUS) [38]. Resins (neutral, anionic,
and cationic) separate substances that are protein-bound
and cannot be removed by dialysis, such as bilirubin, bile
acids, and barbiturates-nephrotoxic drugs from plasma.
However, it causes hypotension, thrombocytopenia,
leukopenia, and bleeding since it also holds clotting factors
and other molecules [39]. The hemoperfusion method is
applied in 4–5 h sessions, and the pump speed is adjusted
to 160 mL/h during the procedure.
5.2.1.4. Albumin dialysis (MARS and PROMETHEUS)
MARS (Molecular Adsorbent Recirculating System,
Gambro AB, Stockholm, Sweden) or PROMETHEUS
(Fractionated Plasma Separation, Adsorption, and
Dialysis system, Fresenius Medical Care AG & Co. KGaA,
Homburg, Germany) can be applied via the vascular route
used in the treatment of continuous renal replacement.
MARS consists of three main units. Continuous albumin
dialysis circuit allows removal of protein-bound toxins
(polysulfone membrane that allows passage of molecules
smaller than 60 kDa that albumin cannot pass). The column
that holds toxins bound to albumin reactivates albumin
and ensures a return to circulation, thus preventing the
support of albumin in large volumes. A continuous renal
replacement circuit allows for classic hemofiltration or
hemodialysis. The MARS cartridge needs to be replaced
every 8 h [40–43]. In the PROMETHEUS system, the
plasma of the patient containing albumin is separated by a
membrane with a molecular permeability of 250 kDa and
passed through two columns with different adsorbents.
The substances dissolved in water are cleaned with a high
exchange dialyzer. With both methods, the excretion
of water-soluble metabolites such as ammonia, urea,
creatinine, and albumin-bound substances such as bile
acid and bilirubin is effective.
In nonbiological support units, heparinization is
generally systemic, but rarely applied regionally (heparin
infusion is initiated before the filter, and 10–20 mg/h
protamine is given to the circulation after the filter).
Heparin is given with a dose of 5–10 u/kg, ACT 200–250,
and PTT are kept in the range of 1.5–2 times the normal
value. Anticoagulation is not applied in patients with
thrombocytopenia (<80,000/mL) or in plasmapheresis
using isotonic NaCl solution as the clot is unlikely to form in
the filter. With the application of citrate and anticoagulant,

1497

OCAK et al. / Turk J Med Sci
which have been used recently, complications related to
heparin have also been eliminated. Citrate-anticoagulant
application is included in the set. It is also neutralized with
Calcium. Problems that may be encountered in applications
with nonbiological support units are summarized in Table
4.
5.2.1.5. Treatment algorithm
Nonbiological support units are activated in the presence
of problems that arise or become more prominent during
medical support treatment in the treatment of liver failure
[44]. Although there is no consensus on which of the
nonbiological support units should be started in patients
who comply with the clinical parameters indicated in
Figure 3, our preferred algorithm is summarized. When
the occurrences that dominate the clinical course of liver
failure (HRS, encephalopathy, hyperbilirubinemia, hepatopulmonary syndrome, and multiorgan failure-MOF) are
considered, treatments are shaped by emphasizing the
different features of the support units. Treatment of CVVH
or CVVHDF is preferred as the first option in the liver failure
table dominated by HRS, plasma exchange, and CRRT or
albumin dialysis and CRRT should be used together if there
is no response. CVVH or CVVHDF is preferred in the
occurrence of liver failure dominated by hepato-pulmonary
syndrome, plasma exchange and CRRT or albumin dialysis
and CRRT should be used together in unanswered cases.
In liver failure, where mild hepatic encephalopathy is
dominant, CVVH or CVVHDF is preferred as the first
approach. In the presence of severe encephalopathy,

plasmapheresis and controlled hypothermia are applied
in addition to these treatments. In cases where there is no
response to these treatments, plasma exchange and CRRT
or albumin dialysis and CRRT should be used together.
In the liver failure table where only hyperbilirubinemia
is dominant, plasmapheresis treatment is started; plasma
exchange and CRRT or albumin dialysis and CRRT should
be used together if no response is obtained. Plasmapheresis,
hemoperfusion, or albumin dialysis can be used as
the first option in cases where hepatic encephalopathy
is accompanied by hyperbilirubinemia and bleeding
parameters are normal. In cases where there is no response,
plasma exchange and CRRT or albumin dialysis and CRRT
should be used together. Plasma exchange should be used
as the first choice in cases where hyperbilirubinemia is
accompanied by hepatic encephalopathy and bleeding
parameters are impaired. In cases where there is no
response, plasma exchange and CRRT or albumin dialysis
and CRRT should be used together. Unlike other clinical
pictures, plasma exchange and CRRT or albumin dialysis
and CRRT should be used together in the MOF table.
When the transaction costs of nonbiological support
units are examined, a fixed expense of around 5000 €
is required per session in MARS or PROMETHEUS
applications (the prices of extracorporeal pump machines
are ignored). Fixed expenditure per session varies between
100 and 1000 € in CRRT [24]. The fixed expense is around
1000 € per session in plasma exchange applications. CRRT
and plasma exchange applications come to the fore as

Table 4. Potential complications of nonbiological support system applications.
System

Complications

Cardiovascular system

Hypotension; hypovolemia, cardiac dysfunction or air embolism
Angina, myocardial infarction
Cardiac dysrhythmias
Steal syndrome; decrease of blood flow at distal to the vascular access

Respiratory system

Pulmonary alterations caused by hypoxemia, air embolism, leukocyte or complement induction

Neurological system

Disequilibrium syndrome; mental confusion, delirium, coma, seizure
Muscle cramps

Hematological system

Bleeding, leukopenia, thrombocytopenia, hemolysis, DIC (mostly due to application of heparin)

Metabolic

Electrolyte and acid-base disorders

Dialysis problems

Dialysis rupture and clotting (occlusion)
Dialysate contamination (fluoride)
Mechanical complications

Problems with vascular access

Thrombosis and infection

Other

Allergic and bio-incompatibility reactions

DIC: disseminated intravascular coagulation.
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Figure 3. Flow diagram of nonbiological liver support systems in cases of liver failure. MOF: multiorgan failure; PT: prothrombin time;
INR: international normalized ratio; PP: plasmapheresis; PE: plasmaexchange; CRRT; continuous renal replacement therapy; Albumin
dialysis; MARS (Molecular Adsorbent Recirculating System) and PROMETHEUS (fractionated plasma separation, adsorption, and
dialysis).

more economical options in the creation of the treatment
algorithm when considering the costs mentioned above.
5.2.2. Biological liver support systems
In a study conducted for the first time in 1956, urea was
obtained from ammonium chloride using homogenate
obtained from cow liver [45]. This study was followed by
studies using the liver from many different animal species
[38]. The complexity of the preparation process and the
loss of effectiveness of the prepared homogenate in a short
time made it difficult to adapt this approach to clinical
use. The livers of different kinds of animals were used
for perfusion (xenogenic extracorporeal liver perfusion)
and the improvements in biochemical parameters and
neurological signs were noted in a limited number of

clinical studies [46,47]. The successful level achieved in
hepatocyte isolation techniques paved the way for the use
of hepatocytes in different configurations in liver support
systems. The usage area of hepatocytes in liver failure can be
summarized under two headings; implantation (hepatocyte
transplantation) and extracorporeal systems. The beneficial
effects of human hepatocyte transplantation in the treatment
of liver failure have been demonstrated in a limited number
of case reports [48]. However, there is no data on the use
of xenogenic hepatocyte transplantation in the treatment
of liver failure in humans. The most important obstacle to
hepatocyte transplantation treatment is that toxic or viral
factors leading to liver failure prevent the transplanted
hepatocytes from organizing [38].
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Table 5. Major bioartificial liver support systems in clinical use.
ELAD

HepatAssist

TECA-HALSS

BLSS

RFB

AMC-BAL

Study group

Houston

Los Angeles

Beijing

Pittsburgh

Cavezzo

Amsterdam

Cell type

Human

Pig

Pig

Pig

Pig

Pig

Cell source

C3A Culture

Cryopreserve

Freshisolation

Freshisolation

Freshisolation

Freshisolation

Cell quantity

200–400 g

5–7 × 109

10–20 × 109

70–120 g

200–230 g

10 × 109

Treatment duration

Max 168 h

6h

Max 5 h

12 h

Max 24 h

Anticoagulation

Heparin

Citrate

Heparin

Heparin

Additional detoxification

None

Coal

Coal

None

Max 24 h
Heparin /
Citrate
None

Yes

None

None

None

None

Randomized controlled study Yes

Heparin
None

ELAD: extracorporeal liver assist device; TECA-HALSs: TECA-hybrid artificial liver support system; BLSS: bioartificial liver support
system; RFB: radial flow bioreactor; AMC-BAL: AMC-bioartificial liver.

Extracorporeal systems or bioartificial liver support
systems have been developed to perform detoxification by
intermittently connecting to the human circulatory system,
just like nonbiological systems. These systems consist of
two main parts. The artificial unit consists of a bioreactor
and parts of this reactor, while the other unit, the biological
unit, consists of hepatocytes [38]. For the first time in 1987,
Matsumura et al. placed isolated rabbit hepatocytes in the
unit of the device separated from the patient’s circulation
by cellulose membrane in a treatment they applied to a
45-year-old patient undergoing hepatic insufficiency due
to inoperable biliary tract tumor [49]. Two years after
this case report, Margulis et al. used the support unit with
pig hepatocytes in their 126 patient series, providing a
significant survival advantage, especially for patients before
the coma [50]. Today, there are many bioartificial liver
support systems developed by different study groups and
used in clinical studies (Table 5). The human hepatocyte
cell line (C3A) was used only in the ELAD (Extracorporeal
Liver Assist Device) system among these systems. These
cells have been cloned from the human hepatoblastoma
cell line, their tumor-forming activities have been reduced
and their albumin-alpha fetoprotein production activities
have been increased [51]. In other systems, pig hepatocytes
are used [52–56]. In Table 5, the cost of treatment of
bioartificial liver support systems, which are briefly
explained as working systems and treatment processes,
is around 50,000–60,000 € and therefore not primarily
preferred in our country and European countries [24].

6. Conclusion
PHLF continues to be a serious surgical complication
of the liver occurring in approximately 10% of patients
undergoing major liver surgery. PHLF ranges from a
mild hepatic impairment, characterized by transient
hyperbilirubinemia, to hepatic impairment, which causes
multiple system insufficiency that requires invasive
treatment in the intensive care unit. Neoadjuvant therapy
with obesity, diabetes, chemotherapy, underlying cirrhosis,
increased age, male sex, extended liver resection need,
and long-term operation with high intraoperative EBL
(estimated blood loss) increases the risk of PHLF. Early start
of the liver support systems is very important for the PHLF
patient to recover, survive, or be ready for a liver transplant.
The nonbiological and biological liver support systems
described above should be used for treatment or organ
transplant in PHLF, and the method of application should
be with the joint approach of the Organ Transplant Clinic
and Intensive Care Unit. The most effective treatment of
liver failure is a liver transplant. However, since the organ
pool is far from meeting expectations, both biological and
nonbiological liver support systems should be expected to
be used more and more effectively in the treatment of PHLF
in the future.
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